Survodutide is a potent and long-acting dual agonist of the GLP?1 receptor (GLP?1R) and glucagon receptor (GCGR), designed for advanced preclinical laboratory research focusing on metabolic diseases, energy balance, glycemic control and adipocyte metabolism. Unlike single-target GLP?1 analogues that mainly regulate appetite and insulin release, this dual agonist delivers combined biological actions from both receptor pathways, creating a synergistic metabolic profile. Activation of GLP?1R mediates glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying and reduced feeding motivation, which helps stabilize blood glucose levels and lower calorie intake. Meanwhile, GCGR stimulation boosts hepatic fat oxidation, elevates whole-body energy expenditure and promotes lipolysis in adipose tissue, supporting the investigation of fat mass reduction mechanisms.

Manufactured via standardized solid-phase peptide synthesis, the crude product undergoes multi-step HPLC purification. Every production batch is validated with mass spectrometry to confirm the accurate amino acid sequence and molecular mass. Routine quality control tests include HPLC purity analysis, water content, residual organic solvent, heavy metal and endotoxin detection to satisfy strict in vitro and in vivo research requirements. The product is provided as sterile lyophilized powder to maintain chemical stability during transportation and long-term storage. After reconstitution with appropriate aqueous buffer, it can be applied to cell culture assays, tissue incubation studies and animal model experiments. Research projects frequently involve the evaluation of body weight change, insulin sensitivity, liver lipid accumulation, inflammatory markers and long-term metabolic adaptation in obesity and type 2 diabetes models. Its unique dual-target mechanism makes it a valuable research tool for exploring next-generation therapeutic strategies against metabolic syndromes.